Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Dec;76(12):1624–1629. doi: 10.1136/jnnp.2005.063388

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

I Masse 1, R Bordet 1, D Deplanque 1, K Al 1, F Richard 1, C Libersa 1, F Pasquier 1
PMCID: PMC1739466  PMID: 16291883

Abstract

Background: Data from epidemiological studies and animal models imply that disturbances in cholesterol metabolism are linked to Alzheimer's disease susceptibility. Lipid lowering agents (LLAs) may have implications for the prevention of Alzheimer's disease.

Objective: To investigate whether LLAs are associated with a slower cognitive decline in Alzheimer's disease.

Methods: An observational study in 342 Alzheimer patients followed in a memory clinic for 34.8 months (mean age 73.5 years, mini-mental state examination score (MMSE) 21.3 at entry); 129 were dyslipaemic treated with LLAs (47% with statins), 105 were untreated dyslipaemic, and 108 were normolipaemic. The rate of cognitive decline was calculated as the difference between the first and last MMSE score, divided by the time between the measurements, expressed by year. Patients were divided into slow and fast decliners according to their annual rate of decline (lower or higher than the median annual rate of decline in the total population).

Results: Patients treated with LLAs had a slower decline on the MMSE (1.5 point/year, p = 0.0102) than patients with untreated dyslipaemia (2.4 points/year), or normolipaemic patients (2.6 points/year). Patients with a slower decline were more likely to be treated with LLAs. Logistic regression analysis, with low annual cognitive decline as the dependent variable, showed that the independent variable LLA (treated with or not) was positively associated with the probability of lower cognitive decline (odds ratio = 0.45, p = 0.002).

Conclusions: LLAs may slow cognitive decline in Alzheimer's disease and have a neuroprotective effect. This should be confirmed by placebo controlled randomised trials in patients with Alzheimer's disease and no dyslipaemia.

Full Text

The Full Text of this article is available as a PDF (89.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkenhäger W. H., Wang J. G., Staessen J. A. Dementia and statins. Lancet. 2001 Mar 17;357(9259):880–881. doi: 10.1016/S0140-6736(00)04187-8. [DOI] [PubMed] [Google Scholar]
  2. Bodovitz S., Klein W. L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996 Feb 23;271(8):4436–4440. doi: 10.1074/jbc.271.8.4436. [DOI] [PubMed] [Google Scholar]
  3. Borroni Barbara, Pettenati Carla, Bordonali Tania, Akkawi Nabil, Di Luca Monica, Padovani Alessandro. Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease. Neurosci Lett. 2003 Jun 12;343(3):213–215. doi: 10.1016/s0304-3940(03)00336-7. [DOI] [PubMed] [Google Scholar]
  4. Cheung B. M., Kumana C. R. Dementia and statins. Lancet. 2001 Mar 17;357(9259):880–881. doi: 10.1016/s0140-6736(05)71806-7. [DOI] [PubMed] [Google Scholar]
  5. Clark C. M., Sheppard L., Fillenbaum G. G., Galasko D., Morris J. C., Koss E., Mohs R., Heyman A. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol. 1999 Jul;56(7):857–862. doi: 10.1001/archneur.56.7.857. [DOI] [PubMed] [Google Scholar]
  6. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):416–418. doi: 10.1136/jnnp.57.4.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., Edwards S., Hardyman W., Raftery J., Crome P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004 Jun 26;363(9427):2105–2115. doi: 10.1016/S0140-6736(04)16499-4. [DOI] [PubMed] [Google Scholar]
  8. Crisby Milita, Carlson Lars A., Winblad Bengt. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):131–136. doi: 10.1097/00002093-200207000-00001. [DOI] [PubMed] [Google Scholar]
  9. Decarli Charles. Vascular factors in dementia: an overview. J Neurol Sci. 2004 Nov 15;226(1-2):19–23. doi: 10.1016/j.jns.2004.09.005. [DOI] [PubMed] [Google Scholar]
  10. Deplanque Dominique, Gelé Patrick, Pétrault Olivier, Six Isabelle, Furman Christophe, Bouly Muriel, Nion Stéphane, Dupuis Bernard, Leys Didier, Fruchart Jean-Charles. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003 Jul 16;23(15):6264–6271. doi: 10.1523/JNEUROSCI.23-15-06264.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ebrahim S., Shlomo Y. B., Smith G. D., Whincup P., Emberson J. Dementia and statins. Lancet. 2001 Mar 17;357(9259):882–882. doi: 10.1016/S0140-6736(05)71811-0. [DOI] [PubMed] [Google Scholar]
  12. Esiri M. M., Nagy Z., Smith M. Z., Barnetson L., Smith A. D. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999 Sep 11;354(9182):919–920. doi: 10.1016/S0140-6736(99)02355-7. [DOI] [PubMed] [Google Scholar]
  13. Evans R. M., Hui S., Perkins A., Lahiri D. K., Poirier J., Farlow M. R. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004 May 25;62(10):1869–1871. doi: 10.1212/01.wnl.0000125323.15458.3f. [DOI] [PubMed] [Google Scholar]
  14. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 Apr 10;98(10):5856–5861. doi: 10.1073/pnas.081620098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von Bergmann K. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002 Oct 22;59(8):1257–1258. doi: 10.1212/wnl.59.8.1257. [DOI] [PubMed] [Google Scholar]
  16. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  17. Frears E. R., Stephens D. J., Walters C. E., Davies H., Austen B. M. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 1999 Jun 3;10(8):1699–1705. doi: 10.1097/00001756-199906030-00014. [DOI] [PubMed] [Google Scholar]
  18. Fruchart J. C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999 Jun;10(3):245–257. doi: 10.1097/00041433-199906000-00007. [DOI] [PubMed] [Google Scholar]
  19. Golomb B. A., Jaworski B. Statins and dementia. Arch Neurol. 2001 Jul;58(7):1169–1170. doi: 10.1001/archneur.58.7.1169. [DOI] [PubMed] [Google Scholar]
  20. Haley R. W., Dietschy J. M. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol. 2000 Oct;57(10):1410–1412. doi: 10.1001/archneur.57.10.1410. [DOI] [PubMed] [Google Scholar]
  21. Han L., Cole M., Bellavance F., McCusker J., Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr. 2000 Jun;12(2):231–247. doi: 10.1017/s1041610200006359. [DOI] [PubMed] [Google Scholar]
  22. Howland D. S., Trusko S. P., Savage M. J., Reaume A. G., Lang D. M., Hirsch J. D., Maeda N., Siman R., Greenberg B. D., Scott R. W. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem. 1998 Jun 26;273(26):16576–16582. doi: 10.1074/jbc.273.26.16576. [DOI] [PubMed] [Google Scholar]
  23. Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C., Larson E. B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 1995 Jun;45(6):1092–1096. doi: 10.1212/wnl.45.6.1092. [DOI] [PubMed] [Google Scholar]
  24. Jellinger K. A. Small concomitant cerebrovascular lesions are not important for cognitive decline in severe Alzheimer disease. Arch Neurol. 2001 Mar;58(3):520–521. doi: 10.1001/archneur.58.3.520. [DOI] [PubMed] [Google Scholar]
  25. Jick H., Zornberg G. L., Jick S. S., Seshadri S., Drachman D. A. Statins and the risk of dementia. Lancet. 2000 Nov 11;356(9242):1627–1631. doi: 10.1016/s0140-6736(00)03155-x. [DOI] [PubMed] [Google Scholar]
  26. Kalaria R. N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000 Mar-Apr;21(2):321–330. doi: 10.1016/s0197-4580(00)00125-1. [DOI] [PubMed] [Google Scholar]
  27. Kivipelto M., Helkala E. L., Hänninen T., Laakso M. P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001 Jun 26;56(12):1683–1689. doi: 10.1212/wnl.56.12.1683. [DOI] [PubMed] [Google Scholar]
  28. Launer L. J., White L. R., Petrovitch H., Ross G. W., Curb J. D. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001 Oct 23;57(8):1447–1452. doi: 10.1212/wnl.57.8.1447. [DOI] [PubMed] [Google Scholar]
  29. Lee J. H., Olichney J. M., Hansen L. A., Hofstetter C. R., Thal L. J. Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol. 2000 Oct;57(10):1474–1479. doi: 10.1001/archneur.57.10.1474. [DOI] [PubMed] [Google Scholar]
  30. Lesser G. T., Libow L. S. Statin-Alzheimer disease association not yet proven. Arch Neurol. 2001 Jun;58(6):1022–1023. doi: 10.1001/archneur.58.6.1022-a. [DOI] [PubMed] [Google Scholar]
  31. Li G., Higdon R., Kukull W. A., Peskind E., Van Valen Moore K., Tsuang D., van Belle G., McCormick W., Bowen J. D., Teri L. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004 Nov 9;63(9):1624–1628. doi: 10.1212/01.wnl.0000142963.90204.58. [DOI] [PubMed] [Google Scholar]
  32. Lopez O. L., Becker J. T., Wisniewski S., Saxton J., Kaufer D. I., DeKosky S. T. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):310–314. doi: 10.1136/jnnp.72.3.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. McKeith I. G., Galasko D., Kosaka K., Perry E. K., Dickson D. W., Hansen L. A., Salmon D. P., Lowe J., Mirra S. S., Byrne E. J. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996 Nov;47(5):1113–1124. doi: 10.1212/wnl.47.5.1113. [DOI] [PubMed] [Google Scholar]
  34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  35. Morris J. C., Edland S., Clark C., Galasko D., Koss E., Mohs R., van Belle G., Fillenbaum G., Heyman A. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993 Dec;43(12):2457–2465. doi: 10.1212/wnl.43.12.2457. [DOI] [PubMed] [Google Scholar]
  36. Mungas D., Reed B. R., Ellis W. G., Jagust W. J. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol. 2001 Aug;58(8):1243–1247. doi: 10.1001/archneur.58.8.1243. [DOI] [PubMed] [Google Scholar]
  37. Notkola I. L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14–20. doi: 10.1159/000026149. [DOI] [PubMed] [Google Scholar]
  38. Olichney J. M., Galasko D., Salmon D. P., Hofstetter C. R., Hansen L. A., Katzman R., Thal L. J. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology. 1998 Aug;51(2):351–357. doi: 10.1212/wnl.51.2.351. [DOI] [PubMed] [Google Scholar]
  39. Pahan K., Sheikh F. G., Namboodiri A. M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997 Dec 1;100(11):2671–2679. doi: 10.1172/JCI119812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pasquier Florence, Richard Florence, Lebert Florence. Natural history of frontotemporal dementia: comparison with Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17(4):253–257. doi: 10.1159/000077148. [DOI] [PubMed] [Google Scholar]
  41. Puglielli Luigi, Tanzi Rudolph E., Kovacs Dora M. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003 Apr;6(4):345–351. doi: 10.1038/nn0403-345. [DOI] [PubMed] [Google Scholar]
  42. Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K., Pappolla M. A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000 Aug;7(4):321–331. doi: 10.1006/nbdi.2000.0304. [DOI] [PubMed] [Google Scholar]
  43. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., Nishi H., Inoue N., Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001 Jan;154(1):87–96. doi: 10.1016/s0021-9150(00)00468-8. [DOI] [PubMed] [Google Scholar]
  44. Rockwood Kenneth, Kirkland Susan, Hogan David B., MacKnight Chris, Merry Heather, Verreault René, Wolfson Christina, McDowell Ian. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002 Feb;59(2):223–227. doi: 10.1001/archneur.59.2.223. [DOI] [PubMed] [Google Scholar]
  45. Roher A. E., Kuo Y. M., Kokjohn K. M., Emmerling M. R., Gracon S. Amyloid and lipids in the pathology of Alzheimer disease. Amyloid. 1999 Jun;6(2):136–145. doi: 10.3109/13506129909007315. [DOI] [PubMed] [Google Scholar]
  46. Román G. C., Tatemichi T. K., Erkinjuntti T., Cummings J. L., Masdeu J. C., Garcia J. H., Amaducci L., Orgogozo J. M., Brun A., Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993 Feb;43(2):250–260. doi: 10.1212/wnl.43.2.250. [DOI] [PubMed] [Google Scholar]
  47. Sadowski Marcin, Pankiewicz Joanna, Scholtzova Henrieta, Li Yong-sheng, Quartermain David, Duff Karen, Wisniewski Thomas. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res. 2004 Jun;29(6):1257–1266. doi: 10.1023/b:nere.0000023612.66691.e6. [DOI] [PubMed] [Google Scholar]
  48. Shepherd James, Blauw Gerard J., Murphy Michael B., Bollen Edward L. E. M., Buckley Brendan M., Cobbe Stuart M., Ford Ian, Gaw Allan, Hyland Michael, Jukema J. Wouter. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623–1630. doi: 10.1016/s0140-6736(02)11600-x. [DOI] [PubMed] [Google Scholar]
  49. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6460–6464. doi: 10.1073/pnas.95.11.6460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Simons M., Keller P., Dichgans J., Schulz J. B. Cholesterol and Alzheimer's disease: is there a link? Neurology. 2001 Sep 25;57(6):1089–1093. doi: 10.1212/wnl.57.6.1089. [DOI] [PubMed] [Google Scholar]
  51. Simons Mikael, Schwärzler Frank, Lütjohann Dieter, von Bergmann Klaus, Beyreuther Konrad, Dichgans Johannes, Wormstall Henning, Hartmann Tobias, Schulz Jörg B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002 Sep;52(3):346–350. doi: 10.1002/ana.10292. [DOI] [PubMed] [Google Scholar]
  52. Snowdon D. A., Greiner L. H., Mortimer J. A., Riley K. P., Greiner P. A., Markesbery W. R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997 Mar 12;277(10):813–817. [PubMed] [Google Scholar]
  53. Sparks D. L. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann N Y Acad Sci. 1997 Sep 26;826:128–146. doi: 10.1111/j.1749-6632.1997.tb48466.x. [DOI] [PubMed] [Google Scholar]
  54. Sparks D. L., Martin T. A., Gross D. R., Hunsaker J. C., 3rd Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech. 2000 Aug 15;50(4):287–290. doi: 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  55. Stern R. G., Mohs R. C., Davidson M., Schmeidler J., Silverman J., Kramer-Ginsberg E., Searcey T., Bierer L., Davis K. L. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 Mar;151(3):390–396. doi: 10.1176/ajp.151.3.390. [DOI] [PubMed] [Google Scholar]
  56. Streit W. J., Sparks D. L. Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med (Berl) 1997 Feb;75(2):130–138. doi: 10.1007/s001090050097. [DOI] [PubMed] [Google Scholar]
  57. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000 Oct;57(10):1439–1443. doi: 10.1001/archneur.57.10.1439. [DOI] [PubMed] [Google Scholar]
  58. Yaffe Kristine, Barrett-Connor Elizabeth, Lin Feng, Grady Deborah. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002 Mar;59(3):378–384. doi: 10.1001/archneur.59.3.378. [DOI] [PubMed] [Google Scholar]
  59. in t' Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M., Stricker B. H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001 Nov 22;345(21):1515–1521. doi: 10.1056/NEJMoa010178. [DOI] [PubMed] [Google Scholar]
  60. van Exel Eric, de Craen Anton J. M., Gussekloo Jacobijn, Houx Peter, Bootsma-van der Wiel Annetje, Macfarlane Peter W., Blauw Gerard J., Westendorp Rudi G. J. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 2002 Jun;51(6):716–721. doi: 10.1002/ana.10220. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES